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Arsenic, a ubiquitous element present in the
environment, is the main constituent of
more than 200 mineral species on earth (1).
In addition to its natural occurrence in min-
eral deposits, arsenical compounds are used
in many human activities such as manufac-
turing, agriculture, and medicine (2).
Arsenical compounds are transported into
the environment mainly by water from wells
drilled into arsenic-rich geologic strata or by
ambient air during the smelting and burning
of coal (1,2). However, the main route of
arsenic exposure for the general population is
via drinking water (2,3). Epidemiologic
studies have documented that long-term
exposure to inorganic arsenic (InAs) is asso-
ciated with an increased risk of cancer of the
lung, skin, and probably other anatomic sites
(4,5). InAs is also one of major risk factors
for blackfoot disease (BFD), a unique periph-
eral vascular disease identified in endemic
areas of arseniasis in Taiwan where residents
had used high-arsenic–tainted artesian well
water for more than 50 years (6). In addi-
tion, cardiovascular disease, such as ischemic
heart disease and coronary heart disease
(7,8), and cerebrovascular accidents (9) are
also closely related to long-term ingestion of
high-arsenic drinking water. Arsenic is an
unusual environmental toxicant in that it
induces carcinogenesis as well as atheroscle-
rosis in human beings. This dual effect of
arsenic may itself suggest a common mecha-
nism shared by the pathogenic process of
both diseases in their relation to arsenic
exposure. A common pathogenic process
involving cell proliferation has been sug-
gested for the human carcinogenicity and
atherogenicity of long-term exposure to InAs
(10). However, the detailed mechanisms by
which arsenic causes both cancer and athero-
sclerotic lesions in humans are not clear.
In in vitro studies, arsenite, a trivalent
InAs compound, has been shown to induce
morphologic transformation (11), structural
and numeric chromosome changes (12,13),
sister chromatid exchanges (14), gene ampli-
fication (15), and micronuclei formation
(16,17). Arsenite by itself does not induce
gene mutations, but it was shown to potenti-
ate the cytotoxicity, mutagenicity, and clas-
togenicity of several DNA-damaging
compounds (18–20). Barchowsky et al. (21)
recently showed that at noncytotoxic con-
centrations, arsenite increases DNA synthesis
in cultured porcine vascular endothelial cells,
an indication of a mitogenic response. The
detailed mechanisms of arsenic genotoxicity
and mitogenicity in cultured cells require
further elucidation. Recent studies have indi-
cated that arsenite may interfere with signal
transduction pathways either by direct
kinase/phosphatase-enzyme inhibition or by
redox control of the regulatory molecules
(21–24). Furthermore, generation of reactive
oxidants during arsenic metabolism can play
an important role in arsenic-induced injury
(16,25–28). These studies suggest involve-
ment of oxidative stress in the pathogenic
effects of arsenic exposure. 
Oxidative stress, which results when oxy-
gen free radical generation exceeds the body’s
antioxidant defense, has been conventionally
considered to have implications in the patho-
physiology of several human diseases, includ-
ing cancer and atherosclerosis (29–31). To
investigate the effect of arsenic exposure on
oxidative stress at the individual level, we
examined reactive oxidants and antioxidant
capacity in plasma of an arsenic-exposed yet
apparently healthy population, and deter-
mined the relationships of the levels of reac-
tive oxidants and antioxidant capacity in
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Articles
Arsenic is a notorious environmental toxicant known as both a carcinogen and an atherogen in
human beings, but the pathogenic mechanisms are not completely understood. In cell culture
studies, trivalent arsenic enhanced oxidative stress in a variety of mammalian cells, and this associ-
ation may be closely associated with the development of arsenic-related diseases. To investigate
the effect of arsenic exposure on oxidative stress in humans, we conducted a population study to
determine the relationships of blood arsenic to reactive oxidants and antioxidant capacity at the
individual level. We recruited 64 study subjects ages 42–75 years from residents of the Lanyang
Basin on the northeast coast of Taiwan, where arsenic content in well water varies from 0 to ≥
3,000 µg/L. We used a chemiluminescence method, with lucigenin as an ampliﬁer for measuring
superoxide, to measure the plasma level of reactive oxidants. We used the azino-diethyl-benzthia-
zoline sulphate method to determine the antioxidant capacity level in plasma of each study sub-
ject. We determined arsenic concentration in whole blood by hydride formation with an atomic
absorption spectrophotometer. The average arsenic concentration in whole blood of study sub-
jects was 9.60 ± 9.96 µg/L (± SD) with a range from 0 to 46.50 µg/L. The level of arsenic concen-
tration in whole blood of study subjects showed a positive association with the level of reactive
oxidants in plasma (r = +0.41, p = 0.001) and an inverse relationship with the level of plasma
antioxidant capacity (r = –0.30, p = 0.014). However, we found no significant association (p =
0.266) between levels of plasma reactive oxidants and antioxidant capacity. Our results also show
that the lower the primary arsenic methylation capability, the lower the level of plasma antioxi-
dant capacity (p = 0.029). These results suggest that ingestion of arsenic-contaminated well water
may cause deleterious effects by increasing the level of reactive oxidants and decreasing the level
of antioxidant capacity in plasma of individuals. Persistent oxidative stress in peripheral blood
may be a mechanism underlying the carcinogenesis and atherosclerosis induced by long-term
arsenic exposure. Key words: antioxidant capacity, azino-diethyl-benzthiazoline sulfate method,
blood arsenic, chemiluminescence, population study, reactive oxidants, superoxide. Environ
Health Perspect 109:1011–1017 (2001). [Online 26 September 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p1011-1017wu/abstract.htmlplasma to the arsenic concentration in whole
blood of subjects. We also examined influ-
ences of lifestyle characteristics and arsenic
metabolism capability on risk associations for
any possible confounding effect.
Methods
Study area. In Taiwan, well water with high
arsenic levels is clustered in the Lanyang
Basin and in the so-called BFD-endemic area
in southwestern Taiwan (32). The Lanyang
Basin of Ilan County is located on the north-
eastern coast of Taiwan. The arsenic concen-
tration in well water from the Lanyang Basin
area ranges from undetectable to over 3,000
µg/L, and over 50% of surveyed wells con-
tained a level of arsenic below 50 µg/L (33).
Although most of the residents in the
Lanyang Basin use household-owned well
water as their primary drinking source,
arsenic-associated cancers observed in the
BFD-endemic area of southwestern Taiwan
have not yet been found extensively in the
Lanyang Basin. However, a high prevalence
of cerebrovascular diseases associated with
long-term arsenic exposure has recently been
reported in the Lanyang Basin (9).
Subject recruitment and blood collection.
We focused on two villages—Meicheng and
Meifu in Chuangwei Township, Ilan
County—where residents currently use
household-owned water supply wells as their
main drinking source. The total population
age 40 years or over in the two villages was
approximately 1,000 in 1995. Since then, the
population has been regularly followed up for
health status (33). The entire population has
spent most of their lives in their respective
villages (33). The subjects for the present
study were recruited from this population. 
We first classified the population into
four groups according to the arsenic level in
their household well water: ≤ 10 µg/L,
10.1–50 µg/L, 50.1–300 µg/L, and > 300
µg/L. Eighty study subjects were grouped by
exposure level, each group containing 20
individuals about the same age and equal in
sex distribution to those in the other groups.
Each subject was scheduled for a health
examination in a local hospital. During the
hospital visit, each was ﬁrst asked for consent
to join this study. Only study subjects who
gave their consent were recruited for blood
collection and were given a questionnaire-
interview by a nurse in the hospital. All sub-
jects recruited for this study were free of any
clinical symptoms such as inﬂammatory dis-
eases. For each study subject, a 10-mL blood
sample was collected into a heparinized and
aluminum foil-wrapped blood tube under
fasting condition. We stored 3 mL blood
sample at –20°C for use to detect arsenic
content in whole blood as a measurement of
the most recent exposure to arsenic exposure.
The analysis was generally performed within
2 weeks. We centrifuged 2 mL sample to
separate plasma from packed cells for subse-
quent assays of reactive oxidative species and
total antioxidant capacity within 6 hr after
collection. We interviewed subjects using a
formatted questionnaire to obtain relevant
information, including demographic and
lifestyle characteristics such as cigarette
smoking and alcohol and tea consumption,
as well as daily sources of drinking water.
Only current users of household-owned well
water were included in this study. All study
subjects were enrolled between November
1997 and May 1998. 
Determination of arsenic concentration
in whole blood. We determined arsenic con-
tent in whole blood for each study subject.
We chose blood as the biologic indicator of
arsenic exposure to estimate better the rela-
tion between arsenic challenge and the resul-
tant oxidative stress for organs and tissues in
the body. Once digested as a water solution,
arsenic is rapidly transported by the blood to
such organs as the liver, kidneys, lungs,
intestines, and the skin within 24 hr (34).
Although 90% of the bloodborne arsenic is
rapidly cleared (34), blood arsenic level is
still a useful indicator of of continuous
arsenic exposure (35). In contrast, urine
arsenic is the best indicator of recent expo-
sure of several days, and hair or even ﬁnger-
nail concentrations of arsenic can reflect
recent exposure of several months (36).
However, these latter two biologic media for
determining arsenic exposure suffer a time-
lag effect for assessment of their relation to
labile radicals formed in study subjects. 
To determine the arsenic concentration
in whole blood of study subjects, we used a
ﬂame atomic absorption spectrophotometric
method developed by Wang et al. (37) with
slight modiﬁcation. Brieﬂy, 2 mL of concen-
trated HNO3 was added to 1 mL of whole
blood in a digestion ﬂask. The digestion was
maintained at 100°C for 40 min. After addi-
tion of 0.7 mL each of concentrated H2SO4
and HClO4, digestion was continued for
another 60 min. Finally, 1 mL of high-
purity water was added and heated until a
colorless solution was obtained. The solution
was then diluted to 12 mL and quantified
for total arsenic using an atomic absorption
spectrophotometer model Z-8000 and its
accessory Hydride Formation System HFS-2
(Hitachi, Tokyo, Japan). According to a
recovery test for arsenic determination in
this study, the recovery of arsenic added to
ion-free water was 83.2%, and the interassay
variation was 7% (replications = 6).
Measurement of the level of reactive oxi-
dants in plasma. We wrapped heparinized
blood samples obtained from study subjects
in aluminum foil to prevent light exposure
until testing for reactive oxidant levels. To
measure the production of oxygen free radi-
cals in samples, we adopted a chemilumines-
cence method, with slight modification,
using lucigenin (1 mg/mL) as an amplifier
for measuring superoxide (O2
–) (38–40).
Briefly, the blood sample was first cen-
trifuged to separate plasma from packed
cells, and 80 µL of the plasma was immedi-
ately placed in a 96-well dish for oxidative
stress assay using a chemiluminescence ana-
lyzer (TopCount System; Packard, Meriden,
CT, USA). After adding lucigenin, we
counted photon emission from the sample at
10-sec intervals at room temperature under
atmospheric conditions. In a preliminary
experiment, the chemiluminescence level
responded immediately after addition of 200
µL lucigenin [(Sigma, St. Louis, MO, USA)
1 mg/mL in phosphate-buffered saline] and
approached its maximum at 5 min.
Afterward, a steady level lasted for 10 min
without a significant change. Thus, the
chemiluminescence measurement for each
sample was determined at 5 min after addi-
tion of lucigenin to the plasma. For each
sample, the assay was performed in triplicate,
and the reactive oxidant level was expressed
as mean chemiluminescence intensity counts
(counts per 5 min). All samples were
processed in the dark.
Measurement of antioxidant capacity
level in plasma. Plasma was separated within
6 hr of collection by centrifugation and pre-
served at –20°C for antioxidant capacity
assay. We measured plasma antioxidant
capacity within 1 week using the 2,2'-azino-
di[3-ethylbenzthiazoline] sulfonate (ABTS)
assay method (Randox Laboratories, Antrim,
UK). In this assay, incubation of ABTS with
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Table 1. Distribution of age, sex, and arsenic content in blood by arsenic concentration in well water
among 64 residents of the Lanyang Basin, northeastern Taiwan, 1997–1998.
Arsenic concentration in well water (µg/L)
Total ≤ 10 10.1–50 50.1–300 > 300
Characteristic number (n = 15) (n = 13) (n = 15) (n = 21)
Mean age in years (range)  64 56.7 (42–75) 58.6 (45–67) 60.0 (42–71) 54.8 (42–67)
Sex (%)
Male 26 6 (40) 5 (62) 6 (40) 9 (43)
Female 38 9 (60) 8 (38) 9 (60) 12 (57)
Mean arsenic 64 7.2 (8.4) 8.1 (12.9) 10.8 (10.0) 11.4 (9.1)
content in blood, µg/L (SD)H2O2 and a peroxidase (metmyoglobin)
produced the blue-green radical cation
ABTS+, which was measured at a wavelength
of 600 nm. Antioxidants in test plasma dose-
dependently suppressed this color produc-
tion. The system was standardized using
Trolox, a water-soluble vitamin E analogue.
The assay for each sample was performed in
triplicate, and results are expressed as mean
millimoles per liter. 
Genetic indicators of arsenic metabolism
capability. We considered two genetic cate-
gories encoding enzymes implicated in
arsenic metabolism for this study: One
involves methyltransferases of arsenic species;
the other is the glutathione S-transferase
(GST) supergene family. Because sequence
information of arsenic methyltransferases is
not yet available in the literature, it is impos-
sible to investigate the polymorphisms of
these enzymes (41). Instead, arsenic species
and their metabolites—including arsenite,
arsenate, monomethylarsonic acid (MMA),
and dimethylarsinic acid (DMA)—excreted
in urine are often studied to reﬂect personal
arsenic methylation capability (42). In the
present study, we analyzed urinary speciation
for each study subject, and the results were
published in a previous report (43). To indi-
cate an individual’s primary and secondary
methylation capability in arsenic metabo-
lism, we used ratios of MMA to arsenite
combined with arsenate (MMA/InAs) and of
DMA to MMA (DMA/MMA), respectively. 
GSTP1 enzyme has been implicated in
arsenic metabolism (44), and the genetic
polymorphism at the GSTP1 locus is sug-
gested as an important factor in cancer etiol-
ogy (45). To determine the genotype at exon
5 of the GSTP1 gene for study subjects,
DNA was extracted from samples of periph-
eral blood cells collected in 1995 (33), and
assayed for this study using the polymerase
chain reaction–restriction fragment length
polymorphism method (46). We ﬁrst identi-
fied two variant GSTP1 cDNAs represent-
ing alleles of 105 isoleucine (Ile) and 105
valine (Val) forms of the GSTP1 protein.
We then classiﬁed study subjects into Ile/Ile,
Ile/Val, or Val/Val genotypes. GSTP1 activi-
ties are lowest among Val/Val homozygotes,
intermediate among Ile/Val heterozygotes,
and highest among Ile/Ile homozygotes (46).
Statistical analyses. Each individual oxy-
gen free radical measurement was logarithm-
transformed to stabilize the variance and to
cause the distribution to approach normality.
All oxygen free radical values presented in the
ﬁgures and tables are logarithm-transformed.
We used the analysis of variance (ANOVA)
F-test to examine the statistical signiﬁcance of
differences in the assayed end points between
groups of risk factors. We determined associa-
tions between study variables by Pearson’s
product-moment correlation coefﬁcients (r).
We performed linear regression analysis to
examine the effect of arsenic concentration in
whole blood on plasma oxidative stress level
and total antioxidant capacity after control-
ling for confounding factors. The level of sta-
tistical signiﬁcance was p < 0.05.
Results
Characteristics of the study population.
Table 1 shows the age and sex distribution
of study subjects by level of arsenic concen-
tration in well water. We recruited 64 study
subjects (80% response rate) for this study.
The age of participants ranged from 42 to
75 years, with 26 males and 38 females. The
mean and SD of arsenic content in whole
blood of each exposure group are also pre-
sented in Table 1. People who had used well
water with higher arsenic levels had a higher
level of arsenic in their whole blood.
The frequency distribution of (loga-
rithm-transformed) plasma reactive oxidant
levels and antioxidant capacity levels for
study participants are graphed in Figure 1.
The plasma reactive oxidants and antioxi-
dant capacity stratified by age, sex, educa-
tional level, and main occupation are
presented in Table 2. In general, the mean
levels of plasma reactive oxidants and antiox-
idant capacity did not significantly differ
among groups stratified by sex, educational
level, or main occupation. In contrast,
plasma antioxidant capacity decreased with
increased age (β-coefficient = –0.0045, p =
0.014). 
Relationship of reactive oxidants to
blood arsenic levels. The crude association
between levels of plasma reactive oxidants
and arsenic concentration in whole blood is
illustrated in Figure 2A. The reactive oxidant
level was signiﬁcantly correlated with arsenic
concentration in whole blood of study sub-
jects (r = +0.41, p = 0.001). The reactive oxi-
dant level increased 0.013 counts/5 min
(antilog = 1.03 counts) per 1 µg/L increase
in blood arsenic level (p = 0.001). Other
study factors, including cigarette smoking
and alcohol and tea consumption, as well as
three indicators of arsenic metabolism capa-
bility—the ratio of MMA to InAs, ratio of
DMA to MMA, and GSTP1 genotype—
were not significantly (p > 0.05) correlated
to the level of plasma reactive oxidants
(Table 3).
Previous studies have suggested that
oxidative lesions in DNA accumulate with
age and are inversely associated with individ-
ual antioxidant capacity (29). We thus fur-
ther adjusted for the aging effect and
diminished antioxidant capacity in our
regression analyses. As shown in Models I
and II of Table 4, the association of reactive
oxidant level with arsenic content in whole
blood did not change substantially when age
and antioxidant capacity were included in
the analysis.
Relationship of antioxidant capacity to
blood arsenic levels. The distribution of
antioxidant capacity levels in relation to
arsenic concentration in whole blood is
graphed in Figure 2B. Despite the wide vari-
ation in individual antioxidant capacity, we
observed a significant inverse correlation of
plasma antioxidant capacity with arsenic
concentration in whole blood (r = –0.30, p =
0.014). The plasma antioxidant capacity
level decreased 0.0034 mM per 1 µg/L
increase in arsenic content in whole blood (p
= 0.014) as shown in the β-coefﬁcient value
of the regression line.
As shown in Table 3, there were no sig-
nificant (p > 0.05) associations of plasma
antioxidant capacity with lifestyle characteris-
tics, including cigarette smoking and alcohol
and tea consumption. Neither the ratio of
DMA to MMA nor the GSTP1 genotype
was associated with plasma antioxidant
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Figure 1. Frequency distributions of levels of plasma (A) reactive oxidants and (B) antioxidant capacity
among 64 residents consuming arsenic-contaminated well water in the Lanyang Basin, northeastern
Taiwan. The (logarithm-transformed) reactive oxidant level was detected by a chemiluminescence assay
measuring the superoxide anion. Antioxidant capacity level was measured using the ABTS method. 
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1.05 1.15 1.25 1.35 1.45 1.55 1.65capacity in study subjects (p > 0.05). On the
other hand, we observed a significant posi-
tive association between plasma antioxidant
capacity and the ratio of MMA to InAs in
urine (p = 0.029). In other words, the lower
the primary arsenic methylation capability,
the lower the antioxidant capacity level in
plasma. However, the decreased level of
plasma antioxidant capacity caused by blood
arsenic remained signiﬁcant after adjustment
for age and primary arsenic methylation
capability (Models III and IV of Table 4).
Discussion
Our data show that arsenic concentration in
whole blood of individuals is positively asso-
ciated with the level of reactive oxidants and
negatively associated with the antioxidant
capacity level in plasma. The present results,
consistent with what we observed in in vitro
studies, provide evidence that drinking
arsenic-contaminated well water may increase
the levels of oxidative stress in peripheral
blood in humans. The increased level of reac-
tive oxygen radicals in plasma may represent
the net result of increased radical production
and decreased antioxidant activity. However,
in this study, the positive association between
arsenic content in blood and oxygen free rad-
icals in plasma was only partially attributable
to the inverse correlation of blood arsenic to
plasma antioxidants. These results suggest
that arsenic digestion in study subjects
enhances the formation of oxygen free radi-
cals in plasma and reduces the antioxidant
capacity of arsenic-ingesting subjects. 
The free radical theory of arsenic toxicity
has recently been gaining acceptance in cell
culture studies. Further, the superoxide anion
and hydroxy peroxide (H2O2) are the pre-
dominant reactive species produced by cul-
tured cells in response to exposure to arsenite
(16,47,48). Our study demonstrates that
changes in lucigenin-derived chemilumines-
cence levels measuring superoxide in plasma
were positively associated with arsenic con-
centration in whole blood of study subjects.
These data are consistent with the results of
previous studies. However, the detection of
superoxide present in plasma of study sub-
jects by the chemiluminescence method may
very likely underestimate the levels of reactive
oxygen species caused by arsenic ingestion.
Nevertheless, the presence of superoxide in
plasma is consequential, as shown by its sig-
niﬁcant association with blood arsenic con-
centrations in study subjects.
The ABTS method we used in this study
to quantitate antioxidant capacity uses the
ability of test plasma to inhibit the genera-
tion of free radicals by metmyoglobin and
hydrogen peroxide. Previous studies with
cultured cells have shown that several antiox-
idant activities, such as those of superoxide
dismutase (SOD) and catalase, may be mod-
ulated by sodium arsenite, thus accumulat-
ing superoxide and H2O2, respectively
(16,27). In addition to these cellular antioxi-
dant enzymes, nonenzymatic antioxidants,
such as glutathione (GSH), bilirubin, fer-
ritin, and uric acid, as well as exogenous
antioxidant molecules such as α-tocopherol,
β-carotene, and ascorbic acid, also provide
primary defense against extracellular and
intracellular free radicals (49). In this study,
we observed that subjects with higher arsenic
content in whole blood had lower antioxi-
dant capacity in plasma. The antioxidants
measured in plasma of subjects in this study
should represent the components in the
extracellular environment, where levels of
SOD, catalase, GSH, and GSH peroxidase
are often very low (50). Thus, transport or
storage proteins, which inactivate the radical
generation activities of transition metals by
sequestering them, as well as supplementary
vitamins may have been the targets for the
assay in this study. The individual compo-
nents of these extracellular antioxidants and
the ways the antioxidants are suppressed by
ingested arsenic need further elucidation in
future studies.
Results of the present study also show
that the level of antioxidant capacity in
plasma declined with the age of study sub-
jects. The effect of aging on antioxidant
activity has been controversial, depending
upon the populations studied and antioxi-
dants measured (51–54). In this study,
plasma antioxidant capacity was measured
by the ABTS method, which assays the total
capacity of antioxidant defense. Because
antioxidant defense exists as a balanced and
coordinated system, the total capacity of the
antioxidant defense may give a more precise
indication of the relationship between the
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Table 2. Plasma reactive oxidant and antioxidant capacity levels by demographic characteristics among
64 residents of the Lanyang Basin, northeastern Taiwan, 1997–1998.
Reactive oxidants levela Antioxidant capacity levelb
Characteristic Number Mean ± SD p-Valuec Mean ± SD p-Value
Total subjects  64 3.001 ± 0.320 1.424 ± 0.112
Age groups (years)
< 50 13 3.003 ± 0.384 1.473 ± 0.095
50–59 25 3.091 ± 0.341 1.447 ± 0.092
≥ 60 26 2.913 ± 0.244 0.141 1.377 ± 0.124 0.016
Sex
Male 26 2.965 ± 0.315 1.428 ± 0.107
Female 38 3.025 ± 0.325 0.467 1.417 ± 0.121 0.702
Education level
Illiterate 17 3.001 ± 0.300 1.418 ± 0.116
Elementary 45 2.990 ± 0.324 1.428 ± 0.114
Junior high and above 2 3.231 ± 0.520 0.589 1.383 ± 0.040 0.831
Main occupation
Retired 22 2.998 ± 0.316 1.418 ± 0.122
Farming 28 2.929 ± 0.282 1.421 ± 0.122
Others 14 3.149 ± 0.368 0.109 1.438 ± 0.077 0.862
aReactive oxidant level (logarithm-transformed) was detected by a chemiluminescence assay measuring the superoxide
anion (counts/5 min). bAntioxidant capacity level was measured using the ABTS method (mM). cProbability derived from
an ANOVA F-test for the hypothesis that there is no difference between groups.
Figure 2. Correlations of levels of plasma (A) reactive oxidants (y = 0.013x + 2.8755) and (B) antioxidant
capacity (y = –0.0034x + 1.4568) with arsenic concentrations in whole blood among 64 residents of the
Lanyang Basin, northeastern Taiwan, 1997–1998. The (logarithm-transformed) reactive oxidant level was
detected by a chemiluminescence assay measuring the superoxide anion; r = 0.41, p = 0.001. Antioxidant
capacity level was measured using the ABTS method; r = –0.30, p = 0.014.
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)assayed end point and the risk factors. The
total antioxidant capacity of the study sub-
jects in this study decreased 0.0044 mM per
yearly increment in age after adjusting for
blood arsenic (Table 4). Interestingly, the
total antioxidant capacity among Chinese in
the geographic area of the present Taiwan
study is generally lower than that of a Hong
Kong Chinese population assayed in a
previous study by other investigators (51).
The combined effect of aging and chronic
exposure to arsenic of the participants in our
study may explain the difference.
We found no significant correlation of
lifestyle characteristics, such as cigarette smok-
ing and alcohol and tea consumption, with
reactive oxidants level or antioxidant capacity
level in plasma. Smoking-related increases
in oxidized products including nitric oxides
and lipid peroxides have been reported pre-
viously (55,56). The nature of the luci-
genin-based chemiluminescence assay
system for superoxide anion or some
unidentiﬁed characteristics of study subjects
in this study may explain the discrepancy of
ﬁnding no smoking-related oxidative stress.
Ethanol has also been reported to affect
oxidative stress level during its metabolism
(57,58). Tea components have anticancer
properties and act as free-radical scavengers
(59,60). Only a small number of the sub-
jects consumed alcohol or tea in the present
study, so random variation due to the small
sample size may have occurred.
Among the indicators of arsenic metabo-
lism capability, primary arsenic methylation
capability indexed by the ratio of MMA/InAs
had a positive association with plasma antiox-
idant capacity even when adjusted further for
the aging effect and arsenic concentration in
whole blood. This result indicates that a high
capacity for methylating InAs into MMA
may alleviate depletion of the antioxidant
system; that is, MMA lowers the antioxidant
capacity level in plasma less than does InAs.
This is consistent with the notion that
organic arsenic is usually less toxic than InAs
compounds. To elucidate the molecular
mechanism of this methyltransformation, the
genetic polymorphisms of arsenite methyl-
transferase must be identiﬁed. 
GST consists of a large family of xenobi-
otic-metabolizing enzymes that catalyze the
conjugation of reduced GSH to a vast array
of hydrophobic and electrophilic com-
pounds, as well as remove compounds that
can generate reactive oxygen species (61).
GSH has been suggested to be a necessary
component for arsenic metabolism probably
in the initial reduction of arsenate to arsenite
and in subsequent oxidative methylation
(62,63). In the present study, the results
show that individuals with the 105 Val allele
(i.e., lower GSTP1-conjugating activity) had
a higher level of oxidative stress and a lower
level of antioxidant capacity in plasma
(shown in Table 3). However, differences
were not statistically signiﬁcant. The GSTP1
genotype alone may confer a relatively weak
inﬂuence, which may be masked by uniden-
tiﬁed confounding factors.
Excessive oxidative stress has long been
proposed to cause deleterious effects on bio-
logic systems; however, it has been difﬁcult
to prove its association with the develop-
ment of cancers and cardiovascular diseases
in humans. High levels of oxidized products
or low levels of antioxidant status have been
found sporadically in patients with relevant
disease (29–31, 64). Oxidized products
detected in target tissues often represent a
small spectrum of the total DNA damage,
including results from reactive radicals.
Furthermore, a lack of speciﬁcity often limits
the use of oxidized products in population
studies. In the present study, we measured
varying levels of arsenic content in blood in
healthy study subjects with no known
inﬂammation. Oxidative stress, indicated by
blood superoxide level, had a good associa-
tion with the level of blood arsenic among
study subjects. Because blood flows to all
organs, an elevated level of oxidative stress in
whole blood may exert a pathogenic effect in
target tissues. Arsenic-induced oxidants, such
as the superoxide anion and hydroxy perox-
ide, have been implicated in in vitro studies
(16,27). These oxidants are suggested to
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Table 3. Plasma reactive oxidant and antioxidant capacity levels by lifestyle characteristics and arsenic
metabolism capability among 64 residents of the Lanyang Basin, northeastern Taiwan, 1997–1998.
Reactive oxidant levelb Antioxidant capacity levelc
Characteristic Numbera Mean ± SD p-Valued Mean ± SD p-Value
Lifestyle characteristic
Cigarette smoking
No 44 2.995 ± 0.345 1.432 ± 0.106
Yes 20 3.013 ± 0.318 0.834 1.405 ± 0.127 0.372
Alcohol consumption
No 59 2.991 ± 0.320 1.428 ± 0.108
Yes 5 3.108 ± 0.329 0.439 1.376 ± 0.166 0.321
Tea consumption
No 58 2.994 ± 0.325 1.421 ± 0.116
Yes 6 3.063 ± 0.284 0.618 1.455 ± 0.065 0.484
Arsenic metabolism capability
MMA/InAs ratio
< 1.8 20 3.072 ± 0.424 1.380 ± 0.112
1.8–3.0 21 2.907 ± 0.190 1.449 ± 0.113
≥ 3.0 21 3.047 ± 0.306 0.209 1.462 ± 0.077 0.029
DMA/MMA ratio
< 1.9 21 3.034 ± 0.337 1.468 ± 0.083
1.9–2.9 20 3.030 ± 0.191 1.412 ± 0.109
≥ 2.9 21 2.960 ± 0.408 0.710 1.412 ± 0.120 0.156
GSTP1 genotype
Ile/Ile  40 2.962 ± 0.240 1.426 ± 0.112
Ile/Val or Val/Val 20 3.101 ± 0.450 0.124 1.407 ± 0.121 0.556
aThere were two subjects without data on arsenic metabolism capability, and four subjects without data on GSTP1 geno-
type. bReactive oxidant level (logarithm-transformed) was detected by a chemiluminescence assay measuring the super-
oxide anion (counts/5 min). cAntioxidant capacity level was measured using the ABTS method (mM). dProbability derived
from an ANOVA F-test for the hypothesis that there is no difference between groups.
Table 4. Multiple linear regression analyses of plasma reactive oxidant and antioxidant capacity levels
among 64 residents of the Lanyang Basin, northeastern Taiwan, 1997–1998.
Coefﬁcient SEa
Model Variable (× 100) (× 100) p-Valueb
Reactive oxidants levelc
I Age (1-year increment) –0.61 0.48 0.214
Arsenic content in blood (1-µg/L increment) 1.31 0.37 0.001
II Age (1-year increment) –0.79 0.51 0.127
Total antioxidant capacity (1-mM increment) –40.77 36.33 0.266
Arsenic content in blood (1-µg/L increment) 1.17 0.39 0.004
Antioxidant capacity leveld
III Age (1-year increment) –0.44 0.17 0.012
Arsenic content in blood (1-µg/L increment) –0.34 0.13 0.012
IV Age (1-year increment) –0.35 0.16 0.037
MMA/InAs (< 1.8 vs. 1.8–3.0) 6.21 2.97 0.041
MMA/InAs (< 1.8 vs. ≥ 3.0) 7.86 2.95 0.010
Arsenic content in blood (1-µg/L increment) –0.32 0.12 0.010
aSE of the coefﬁcient, SD/(N-1)0.5; n = 64. bProbability derived from a Wald’s chi-square test for the hypothesis that the
regression coefﬁcient = 0. cReactive oxidant level (logarithm-transformed) was detected by a chemiluminescence assay
measuring the superoxide anion (counts/5 min). dAntioxidant capacity level was measured using the ABTS method (mM).damage macromolecules in cells or to act as
second messengers, leading to alteration of
the gene expression proﬁle in cells and subse-
quent enhancement of cell proliferation
(65,66). The positive association of reactive
oxygen radicals with arsenic content in
blood found in this study may explain why
arsenic induces both cancers and atheroscle-
rotic lesions at several anatomic sites, as we
observed previously among residents of the
arseniasis-endemic area (5,67). Arsenic also
reduces antioxidant levels in plasma, which
may accelerate disease development at target
sites. This contention is consistent with
observations of previous studies that levels of
β-carotene were lower in patients with
arsenic-induced skin cancer (68) as well as in
patients with ischemic heart disease (69)
than in healthy controls. 
In summary, we present evidence that
arsenic in blood is not only associated with
an increased level of reactive oxygen radicals
but is also inversely related to the antioxi-
dant capacity in plasma of humans. The
results of this study indicate that arsenic is a
significant environmental toxicant that
increases the risk of oxidative stress in
exposed persons. Persistent high levels of
oxidative stress may be a mechanism under-
lying the carcinogenesis and atherosclerosis
induced by long-term arsenic exposure.
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